Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue 1, 2001, Pages 19-24

  Feng, Tong Chuang ^a,b   Ying, Wang Yui ^b   Hua, Ren Jang ^e   Ji, Yale Y ^b,d   De Gasparo, Marc ^c  

^a Huben Medical University   (China)

^b WUHAN UNIVERSITY   (China)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Beijing DMS Pharma Ltd   (China)

^e NONE

Author keywords

Angiotensin receptor; Blockade; Bradykinins; Endothelin; Restenosis; Valsartan

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANGIOTENSIN RECEPTOR; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; ENDOTHELIN 1; TETRAZOLE DERIVATIVE; THROMBOXANE B2; VALINE; VALSARTAN;

ANIMAL; ARTICLE; BLOOD; CAROTID ARTERY INJURY; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; INTIMA; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

6-KETOPROSTAGLANDIN F1 ALPHA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CAPTOPRIL; CAROTID ARTERY INJURIES; CELL DIVISION; ENDOTHELIN-1; FEMALE; MALE; RABBITS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; THROMBOXANE B2; TUNICA INTIMA; VALINE;

EID: 0035296078     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2001.003     Document Type: Article

References (57)

1. Berk BC, Harris K. Restenosis after percutaneous transluminal coronary angioplasty: new therapeutic insights from pathogenic mechanisms. Adv Intern Med 1995;40:445-501.
2. Poma JJ, Kunz RE. Pharmacological restenosis trials. In: Topol EJ, and Serruys RV. (eds) Current review of international cardiology: Philadelphia: Current Medicine 1994:1-15.
3. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25(2):362-9.
4. Pepine CJ, Hirshfeld JW, Macdonald RG et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 1990;81(6):1753-61.
5. Weintraub WS, Boccuzzi SJ, Klein JL et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994; 331(20): 1331-7.
6. Guarda E, Myers PR, Brilla CG, Tyagi SC, Weber KT. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res 1993; 27(6):1004-8.
7. 1 receptor subtype. Circ Res 1993;73(3):413-23.
8. Schorb W, Conrad KM, Singer HA, Dostal DE, Baker KM. Ang II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol 1995:27(5):1151-60.
9. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23(6 Pt 2):869-77.
10. Azuma H, Niimi Y, Hamasaki H. Prevention of intimal thickening after endothelial removal by a nonpeptide Ang II receptor antagonist, losartan. Br J Pharmacol 1992; 106(3):665-71.
11. Jandeleit-Dahm K, Burrell LM, Johnston CI, Koch KM. Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats. J Hypertens 1997; 15(6):643-50.
12. Kawamura M, Terashita Z, Okuda H et al. TCV-116, a novel Ang II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 1993; 266(3):1664-9.
13. Laporte S, Escher E. Neointima formation after vascular injury is Ang II mediated. Biochem Biophys Res Commun 1992; 187(3):1510-6.
14. Barton M, Shaw S, d'Uscio LV, Moreau P, Luscher TF. Ang II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997;238(3):861-5.
15. Clavell AL, Mattingly MT, Stevens TL et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 1996;97(5):1286-92.
16. Largo R, Gomez-Garre D, Liu XH et al. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Hypertension 1997; 29(5): 1178-85.
17. Modesti PA, Cecioni I, Naldoni A, Migliorini A, Neri Serneri GG. Relationship of renin-angiotensin system and ET-1 system activation in long-lasting response to postural changes. Am J Physiol 1996;270(4 Pt 2):H1200-6.
18. Tohmo H, Karanko M, Klossner J et al. Enalaprilat decreases plasma endothelin and atrial natriuretic peptide levels and preload in patients with left ventricular dysfunction after cardiac surgery. J Cardiothorac Vasc Anesth 1997; 11(5):585-90.
19. Hatakeyama H, Miyamori I, Yamagishi S et al. Ang II up-regulates the expression of type A endothelin receptor in human vascular smooth muscle cells. Biochem Mol Biol Int 1994; 34(1):127-34.
20. Berthold H, Munter K, Just A, Kirchheim HR, Ehmke H. Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Am J Physiol 1999; 276(3 Pt 2):F417-24.
21. Cheng W, Li B, Kajstura J et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995;96(5):2247-59.
22. Leri A, Claudio PP, Li Q et al. Stretch-mediated release of Ang II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998; 101(7):1326-42.
23. Pierzchalski P, Reiss K, Cheng W et al. p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res 1997; 234(1):57-65.
24. Powell JS, Clozel JP, Muller RK et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245(4914):186-8.
25. 1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991;139(6):1291-6.
26. Hermans WR, Foley DP, Rensing BJ, Serruys PW. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions-further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). Am Heart J 1994; 127(3):483-94.
27. Hermans WR, Rensing BJ, Foley DP et al. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). J Am Coll Cardiol 1992; 20(4):767-80.
28. Inoue K, Nishimura H, Kubota J, Kawamura K. Alternative Ang II formation in rat arteries occurs only at very high concentrations of angiotensin I. Hypertension 1999 34(3):525-30.
29. 2 receptor: fact, fancy and fantasy. Regul Pept 1999; 81(1-3):11-24.
30. Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Ann Rev Pharmacol Toxicol 1996; 36:281-306.
31. Janiak P, Libert O, Vilaine JP. Role of the renin-angiotensin system in neointima formation after injury in rabbits. Hypertension 1994; 24(6):671-8.
32. 1-receptor subtype. Br J Pharmacol 1993; 110(2):761-71.
33. Siragy, H. Ang II receptor blockers: review of the binding characteristics. Am J Cardiol 1999; 84(10A):3S-8S.
34. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997;96(5):1593-7.
35. Rajagopalan S, Laursen JB, Borthayre A et al. Role for endothelin-1 in Ang II-mediated hypertension. Hypertension 1997;30(1 Pt 1):29-34.
36. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M Luscher TF. Effects of chronic ETA-receptor blockade in Ang II-induced hypertension. Hypertension 1997;29(1 Pt 2):435-41.
37. New RB, Sampson AC, King MK et al. The effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: I. Effects on left ventricular performance. Circulation 2000;102(12):1447-53.
38. Badr KF, Jacobson HR. Arachidonic metabolites and the kidney. In: Brenner BM and Rector, FCJ. (eds) The kidney. Philadelphia PA: W.B. Saunders, 1991:584-619.
39. Catalioto RM, Porchia R, Renzetti AR, Criscuoli M, Subissi A, Giachetti A. Ang II-induced responses in vascular smooth muscle cells: inhibition by non-peptide receptor antagonists. Eur J Pharmacol 1995; 280(3):285-92.
40. 1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes. Am J Hypertens 1992; 5(9):648-56.
41. Siragy HM, Carey RM. The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats. Am J Physiol 1997;273(3 Pt 2):R1103-7.
42. 1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996;97(8):1978-82.
43. Catalioto KM, Renzetti AR, Criscuoli M, Mizrahi J, Subissi A. Angiotensins induce the release of prostacyclin from rabbit vas deferens: evidence for receptor heterogeneity. Eur J Pharmacol 1994;256(1):93-7.
44. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104(7):925-35.
45. Das M, Soffer RL. Pulmonary angiotensin-converting enzyme. Structural and catalytic properties. J Biol Chem 1975; 250(17):6762-8.
46. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Am Intern Med 1992; 117(3):234-42.
47. Agata J, Miao RQ, Yayama K, Chao L, Chao J. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 2000; 36(3):364-370.
48. Farhy RD, Ho KL, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992;182(1):283-8.
49. Tanus-Santos JE, Gordo WM, Francisco-DoPrado J, Sampaio RC, Moreno H. Endothelin-1 attenuates bradykinin-induced hypotension in rats. Eur J Pharmacol 2000; 397(2-3):367-71.
50. Stanke-Labesque F, Devillier P, Bedouch P, Cracowski JL, Chavanon O, Bessard G. Ang II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition. Cardiovasc Res 2000; 47(2):376-383.
51. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100(2):264-9.
52. Yamabe T, Imazu M, Yamamoto H et al. Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 1995; 6(7):573-9.
53. Peters S, Götting B, Trümmel M, Rust H, Brattström A. Reduktion der Rezidivstenoserate nach Stenting komplexer Typ B2/C-Stenosen durch Valsartan. Zeitschrift für Kardiologie 1999;88(Supplement 2):Abstract 336.
54. Feener EP, Northrup JM, Aiello LP, King GL. Ang II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95(3):1353-62.
55. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Ang II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90(1):362-8.
56. de las Heras N, Vázquez-Pérez S, Navarro-Cid J et al. Ang II type 1 receptor antagonism prevented the effects of hypercholesterolemia on plasma fibrinolytic balance in rabbits. Abstract submitted for the High BP Council. Washington October 2000.
57. Sironi L, Calvio AM, Arnaboldi L et al. Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 2001; 37(3):961-66.